Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng Road East, Guangzhou 510060, China.
Biomark Res. 2013 Dec 11;1(1):32. doi: 10.1186/2050-7771-1-32.
Although palliative chemotherapy has been shown to prolong survival and improve quality of life, the survival of advanced gastric cancer (AGC) patients remains poor. With the advent of targeted therapy, many molecular targeted agents have been evaluated in clinical studies. Trastuzumab, an anti-HER2 monoclonal antibody, has shown activity against HER2-positive AGC and becomes the first targeted agent approved in AGC. Drugs that target epidermal growth factor receptor, including monoclonal antibody and tyrosine kinase inhibitor, do not bring survival benefit to patients with AGC. Additionally, vascular endothelial growth factor inhibitors are also under investigation. Ramucirumab has shown promising result. Other targeted agents are in preclinical or early clinical development, such as mammalian target of rapamycinm inhibitors and c-MET inhibitors.
虽然姑息化疗已被证明可以延长生存时间并改善生活质量，但晚期胃癌（AGC）患者的生存率仍然很低。随着靶向治疗的出现，许多分子靶向药物已经在临床研究中得到了评估。曲妥珠单抗，一种抗 HER2 单克隆抗体，对 HER2 阳性 AGC 具有活性，成为首个在 AGC 中获得批准的靶向药物。针对表皮生长因子受体的药物，包括单克隆抗体和酪氨酸激酶抑制剂，并未给 AGC 患者带来生存获益。此外，血管内皮生长因子抑制剂也在研究中。雷莫芦单抗显示出有前景的结果。其他靶向药物处于临床前或早期临床开发阶段，如哺乳动物雷帕霉素靶蛋白抑制剂和 c-MET 抑制剂。
